Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Effects of PERK eIF2α Kinase Inhibitor against Toxoplasma gondii.

Augusto L, Martynowicz J, Staschke KA, Wek RC, Sullivan WJ Jr.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01442-18. doi: 10.1128/AAC.01442-18. Print 2018 Nov.

PMID:
30181373
2.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.

Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.

3.

Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.

Krishnamoorthy J, Tenkerian C, Gupta J, Ghaddar N, Wang S, Darini C, Staschke KA, Ghosh A, Gandin V, Topisirovic I, Kristof AS, Hatzoglou M, Simos G, Koromilas AE.

Cell Death Dis. 2018 Feb 15;9(3):254. doi: 10.1038/s41419-018-0326-2.

4.

PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA.

PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec.

5.

mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress.

Tenkerian C, Krishnamoorthy J, Mounir Z, Kazimierczak U, Khoutorsky A, Staschke KA, Kristof AS, Wang S, Hatzoglou M, Koromilas AE.

Mol Cancer Res. 2015 Oct;13(10):1377-88. doi: 10.1158/1541-7786.MCR-15-0184-T. Epub 2015 Jun 30.

6.

Identification of druggable cancer driver genes amplified across TCGA datasets.

Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV, Buchanan S, Peng SB, Staschke KA, Yadav V, Yue Y, Kouros-Mehr H.

PLoS One. 2014 May 29;9(5):e98293. doi: 10.1371/journal.pone.0098293. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107646.

7.

HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication.

He Y, Staschke KA, Tan SL.

In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. Chapter 9.

8.

How do tumours adapt to nutrient stress?

Wek RC, Staschke KA.

EMBO J. 2010 Jun 16;29(12):1946-7. doi: 10.1038/emboj.2010.110. No abstract available.

9.

Integration of general amino acid control and target of rapamycin (TOR) regulatory pathways in nitrogen assimilation in yeast.

Staschke KA, Dey S, Zaborske JM, Palam LR, McClintick JN, Pan T, Edenberg HJ, Wek RC.

J Biol Chem. 2010 May 28;285(22):16893-911. doi: 10.1074/jbc.M110.121947. Epub 2010 Mar 16.

10.

IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.

Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, Hepburn DL, Xia J, Gulen MF, Kang Z, Altuntas CZ, Tuohy VK, Gilmour R, Li X, Na S.

J Immunol. 2009 Jul 1;183(1):568-77. doi: 10.4049/jimmunol.0802361.

11.

Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions.

Zhou D, Palam LR, Jiang L, Narasimhan J, Staschke KA, Wek RC.

J Biol Chem. 2008 Mar 14;283(11):7064-73. doi: 10.1074/jbc.M708530200. Epub 2008 Jan 14.

12.

Dimerization is required for activation of eIF2 kinase Gcn2 in response to diverse environmental stress conditions.

Narasimhan J, Staschke KA, Wek RC.

J Biol Chem. 2004 May 28;279(22):22820-32. Epub 2004 Mar 9.

14.

Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection.

Staschke KA, Colacino JM.

Prog Drug Res. 2001;Spec No:111-83. Review.

PMID:
11548207
17.

Approaches and strategies for the treatment of influenza virus infections.

Colacino JM, Staschke KA, Laver WG.

Antivir Chem Chemother. 1999 Jul;10(4):155-85. Review.

PMID:
10480736
18.

Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid.

Staschke KA, Hatch SD, Tang JC, Hornback WJ, Munroe JE, Colacino JM, Muesing MA.

Virology. 1998 Sep 1;248(2):264-74.

19.
20.

Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2',3'-dideoxy-3'-C-(hydroxymethyl)-beta-D-erythropentofuranosyl] cytosine.

Mauldin SC, Paget CJ Jr, Jones CD, Colacino JM, Baxter AJ, Staschke KA, Johansson NG, Vrang L.

Bioorg Med Chem. 1998 May;6(5):577-85.

PMID:
9629471
21.

A single sequence change destabilizes the influenza virus neuraminidase tetramer.

Colacino JM, Chirgadze NY, Garman E, Murti KG, Loncharich RJ, Baxter AJ, Staschke KA, Laver WG.

Virology. 1997 Sep 15;236(1):66-75.

22.

Differential effects of the incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences.

Staschke KA, Richardson KK, Mabry TE, Baxter AJ, Scheuring JC, Huffman DM, Smith WC, Richardson FC, Colacino JM.

Nucleic Acids Res. 1996 Nov 1;24(21):4111-6.

23.

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.

Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG.

Virology. 1995 Dec 20;214(2):642-6.

Supplemental Content

Loading ...
Support Center